Loading...
•
Sep 30, 2024
Rhythm Pharmaceuticals Q3 2024 Earnings Report
Reported financial results for the third quarter ended September 30, 2024.
Key Takeaways
Rhythm Pharmaceuticals reported Q3 2024 net revenue of $33.3 million from global sales of IMCIVREE. The company's cash position is expected to support operations into 2026.
Net revenue from global sales of IMCIVREE® (setmelanotide) was $33.3 million.
Adult patients with acquired hypothalamic obesity (N=8) achieved mean BMI reduction of 12.8% on setmelanotide therapy at three months in French early-access program.
Top-line data readout for Phase 3 trial evaluating setmelanotide in 120 patients with acquired hypothalamic obesity is on track for 1H 2025.
Cash on-hand is expected to support planned operations into 2026.
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.com Forward Guidance
Rhythm reduced its anticipated Non-GAAP Operating Expenses to approximately $245 million to $255 million for the year ending December 31, 2024.